FRAT1 and meningioma: Taken together, we were able to validate three new direct targets for miR-34a-3p, SMAD4, FRAT1 and BCL2, which are likely to be implicated in the deregulation of signaling pathways that are already known to be involved in meningioma genesis and progression.